Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 13,450 KRW
Change Today +50.00 / 0.37%
Volume 259.1K
083790 On Other Exchanges
Symbol
Exchange
KOSDAQ
As of 2:25 AM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

crystalgenomics inc (083790) Snapshot

Open
13,600
Previous Close
13,400
Day High
13,850
Day Low
13,250
52 Week High
08/4/14 - 19,500
52 Week Low
11/14/14 - 10,250
Market Cap
304.2B
Average Volume 10 Days
334.2K
EPS TTM
-576.00
Shares Outstanding
22.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CRYSTALGENOMICS INC (083790)

Related News

No related news articles were found.

crystalgenomics inc (083790) Related Businessweek News

No Related Businessweek News Found

crystalgenomics inc (083790) Details

CrystalGenomics, Inc., a biopharmaceutical company, operates as a structural chemoproteiomics-based drug discovery and development company in South Korea. Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles. The company’s drug candidates also include CG200745, a histone deacetylase inhibitor for cancer, which is in Phase I clinical trial; and CG400549, an antibiotic candidate for methicillin resistant staphylococcus aureus and vancomycin resistant staphylococcus aureus that has completed Phase I studies in Europe, as well as is in Phase IIa study in the United States. CrystalGenomics, Inc. is based in Seongnam, South Korea.

crystalgenomics inc (083790) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

crystalgenomics inc (083790) Key Developments

CrystalGenomics, Inc., Annual General Meeting, Mar 27, 2015

CrystalGenomics, Inc., Annual General Meeting, Mar 27, 2015., at 09:00 Korea Standard Time. Location: Basement Floor meeting room, Bundang-gu. Agenda: To consider the approval financial statements; to consider the appointment of Directors of the company; to consider the Directors remuneration; to consider the audit remuneration; to consider the stock options; and to consider other issues.

CrystalGenomics Partners with Daewoong Pharmaceutical for Acelex Commercialization in Korea

CrystalGenomics, Inc. announced that it has signed a Sales and Marketing Agreement with Daewoong Pharmaceutical for the commercialization of Acelex (polmacoxib) in Korea. Under the terms of the agreement, Daewoong will secure exclusive rights in Korea to sell and market Acelex, a 2mg capsule novel NSAID developed by CrystalGenomics for the treatment of osteoarthritis. CrystalGenomics will receive an upfront payment and milestone payments from Daewoong and will share profit from sales of Acelex, which is expected to rapidly capture at least 10% of the arthritis market in Korea that is estimated to be worth more than KRW 500 billion per year. Osteoarthritis is quite common in Korea, affecting about 50% of the population aged 65 years or older of which the number of patients is growing at 18% per year due to aging and obesity.

CrystalGenomics Receives MFDS Approval for Acelex® (Polmacoxib)

CrystalGenomics, Inc. announced that it has received approval for Acelex® (polmacoxib) from the Korean Ministry of Food and Drug Safety (MFDS) for the treatment of osteoarthritis. Pre-commercialization will commence immediately and a commercial launch partner for the Korean market will be announced very shortly. Acelex is the first, tissue-specific once-a-day osteoarthritis drug with a novel mode of action that specifically targets affected joints to relieve pain and restore mobility, while simultaneously preserving the integrity and safety of the gastrointestinal and cardiovascular systems. The results from the Phase 3 study suggest that Acelex 2mg once-a-day provides more rapid onset of relief from the signs and symptoms of osteoarthritis in comparison to celecoxib 200mg once-a-day, without added safety risk. Acelex is expected to rapidly capture at least 10% of the arthritis market in Korea that is estimated to be worth more than KRW 500 billion per year as of 2013. Osteoarthritis is quite common in Korea, as it affects about 50% of the population aged 65 years or older. Moreover, the overall number of patients is growing rapidly due to an aging population coupled with an increasing prevalence of obesity.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
083790:KS 13,450.00 KRW +50.00

083790 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ArQule Inc $2.14 USD -0.03
Array BioPharma Inc $7.30 USD -0.31
Exelixis Inc $3.11 USD +0.01
Infinity Pharmaceuticals Inc $14.86 USD -0.28
Rigel Pharmaceuticals Inc $4.09 USD -0.08
View Industry Companies
 

Industry Analysis

083790

Industry Average

Valuation 083790 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 66.6x
Price/Book 5.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 53.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CRYSTALGENOMICS INC, please visit www.cgxinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.